Rigel Pharmaceuticals (RIGL) said Thursday that it has settled with Annora Pharma, Hetero Labs, and Hetero USA, resolving patent litigation related to its product Tavalisse.
Rigel said the litigation arose after Annora submitted an abbreviated new drug application to the US Food and Drug Administration seeking approval for a generic version of Tavalisse.
Rigel said the settlement allows Annora to be licensed to sell its generic version starting in Q2 2032 or earlier under certain conditions.
The settlement also ends all ongoing litigation between Rigel and Annora over Tavalisse patents in New Jersey, Rigel said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。